Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
91-105 of 339
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
MinuteCE®RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
Kathryn Arbour
Eileen M. O'Reilly, MD
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
Kathryn Arbour
Eileen M. O'Reilly, MD
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Kathryn Arbour
Eileen M. O'Reilly, MD
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
Eileen M. O'Reilly, MD
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
MinuteCE®Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
Eileen M. O'Reilly, MD
Kathryn Arbour
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
CME/CEFrontline Insights: Emerging Therapeutic Strategies in HNSCC
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Christophe Le Tourneau, MD, PhD
- advertisement
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
CME/CEBreaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
María-Victoria Mateos, MD, PhD
Interdisciplinary Strategies for BRCA-Mutated EBC: Testing, Targeting, and Team-Based Care
CME/CE Broadcast ReplayInterdisciplinary Strategies for BRCA-Mutated EBC: Testing, Targeting, and Team-Based Care
Jane Meisel, MD
Addressing Unmet Needs in Metastatic Uveal Melanoma
CME/CEAddressing Unmet Needs in Metastatic Uveal Melanoma
Marlana Orloff, MD
Gregory Daniels, MD, PhD
Jesse Keller, MD
Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
CME/CEPatients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
Ryan D. Cassaday, MD
Daniel J. DeAngelo, MD, PhD
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
MinuteCE®Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
A.J. Gelderblom, MD, PhD
Chelsea Cole, MD
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
MinuteCE®Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
A.J. Gelderblom, MD, PhD
Michiel van de Sande, MD, PhD
- advertisement
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
MinuteCE®The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
A.J. Gelderblom, MD, PhD
A.J. Gelderblom, MD, PhD
Michiel van de Sande, MD, PhD
Chelsea Cole, MD
All Sides of the Joint: Integrated TGCT Care Across Specialties
MinuteCE®All Sides of the Joint: Integrated TGCT Care Across Specialties
A.J. Gelderblom, MD, PhD
Michiel van de Sande, MD, PhD
Chelsea Cole, MD
